fgf23 levels  (Cusabio)

Journal: Journal of Orthopaedic Surgery and Research

Article Title: GLP-2 alleviates postmenopausal osteoporosis by acting on osteoblasts through the PI3K/AKT/FOXO1 signalling pathway to downregulate FGF23 expression

doi: 10.1186/s13018-026-06661-2

Figure Lengend Snippet: Transcriptomic analysis of femoral tissues from sham, OVX, and OVX + GLP-2 groups. A Scatter plot of DEGs between the OVX and sham groups (1654 upregulated genes and 2038 downregulated genes). B Scatter plot of DEGs between the OVX + GLP-2 and OVX groups (318 upregulated genes and 396 downregulated genes). C Heatmap of 24 representative DEGs among the three groups. D GO enrichmentresults showing DEGs involved in cellular component, biological process, and molecular function categories. E KEGG signalling pathway diagram. F KEGG enrichment bar chart. G KEGG enrichment scatter plot. H Relative mRNA expression of FGF23, FGF6, and FGF18 in the tibiae of the OVX group

Article Snippet: FGF23 levels in cell culture supernatants were measured using a mouse FGF23 ELISA Kit (CSB-EL008629MO, Cusabio) following the manufacturer’s protocol.

Techniques: Expressing

Journal: Journal of Orthopaedic Surgery and Research

Article Title: GLP-2 alleviates postmenopausal osteoporosis by acting on osteoblasts through the PI3K/AKT/FOXO1 signalling pathway to downregulate FGF23 expression

doi: 10.1186/s13018-026-06661-2

Figure Lengend Snippet: Effects of GLP-2 and the PI3K inhibitor LY294002 on FGF23 expression in OVX mice. Forty-four female C57BL/6J mice were randomly divided into five groups: sham-operated (sham, n = 6), OVX treated with vehicle (OVX, n = 8), OVX treated with GLP-2 (OVX + GLP-2, n = 10), OVX treated with LY294002 (OVX + LY294002, n = 10), and OVX treated with GLP-2 plus LY294002 (OVX + GLP-2 + LY294002, n = 10). A IHC staining of FGF23 in the distal femur and corresponding MOD analysis. B Relative mRNA expression of FGF23 in femurs. C Serum FGF23 levels measured by ELISA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

Article Snippet: FGF23 levels in cell culture supernatants were measured using a mouse FGF23 ELISA Kit (CSB-EL008629MO, Cusabio) following the manufacturer’s protocol.

Techniques: Expressing, Immunohistochemistry, Enzyme-linked Immunosorbent Assay

Journal: Journal of Orthopaedic Surgery and Research

Article Title: GLP-2 alleviates postmenopausal osteoporosis by acting on osteoblasts through the PI3K/AKT/FOXO1 signalling pathway to downregulate FGF23 expression

doi: 10.1186/s13018-026-06661-2

Figure Lengend Snippet: GLP-2 downregulates FGF23 expression by activating GLP-2R/PI3K/AKT signalling in osteoblasts. A Western blot analysis of AKT and p-AKT levels in osteoblasts with or without shRNA-GLP-2R interference. B Relative mRNA expression of FGF23 in osteoblasts treated with or without shRNA-GLP-2R. C Western blot analysis of AKT and p-AKT levels in cells treated with or without LY294002. D Relative mRNA expression of FGF23 following LY294002 intervention. E Western blot analysis of AKT and p-AKT levels in cells treated with or without MK-2206. F Relative mRNA expression of FGF23 after MK-2206 treatment. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

Article Snippet: FGF23 levels in cell culture supernatants were measured using a mouse FGF23 ELISA Kit (CSB-EL008629MO, Cusabio) following the manufacturer’s protocol.

Techniques: Expressing, Western Blot, shRNA

Journal: Journal of Orthopaedic Surgery and Research

Article Title: GLP-2 alleviates postmenopausal osteoporosis by acting on osteoblasts through the PI3K/AKT/FOXO1 signalling pathway to downregulate FGF23 expression

doi: 10.1186/s13018-026-06661-2

Figure Lengend Snippet: GLP-2 regulates FGF23 expression via the inactivation of FOXO1. A Western blot analysis of FOXO1 and p-FOXO1 levels in osteoblasts treated with or without GLP-2. B Immunofluorescence staining of FOXO1 in osteoblasts (green), counterstained with DAPI (blue). C Relative mRNA expression of FGF23 in osteoblasts treated with the FOXO1 inhibitor AS1842856. D Verification of FOXO1 overexpression by Western blot after PCDH-FOXO1 transfection. E Effect of FOXO1 overexpression on FGF23 mRNA levels in osteoblasts with or without GLP-2 treatment. F Effect of FOXO1 overexpression on the FGF23 concentration in the cell culture supernatant. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

Article Snippet: FGF23 levels in cell culture supernatants were measured using a mouse FGF23 ELISA Kit (CSB-EL008629MO, Cusabio) following the manufacturer’s protocol.

Techniques: Expressing, Western Blot, Immunofluorescence, Staining, Over Expression, Transfection, Concentration Assay, Cell Culture

Journal: Journal of Orthopaedic Surgery and Research

Article Title: GLP-2 alleviates postmenopausal osteoporosis by acting on osteoblasts through the PI3K/AKT/FOXO1 signalling pathway to downregulate FGF23 expression

doi: 10.1186/s13018-026-06661-2

Figure Lengend Snippet: Mechanistic diagram illustrating how GLP-2 downregulates FGF23 to ameliorate postmenopausal osteoporosis via the GLP-2R/PI3K/AKT/FOXO1 signalling pathway

Article Snippet: FGF23 levels in cell culture supernatants were measured using a mouse FGF23 ELISA Kit (CSB-EL008629MO, Cusabio) following the manufacturer’s protocol.

Techniques:

Journal: Frontiers in Nephrology

Article Title: Role of kidney transplantation in long-term cardiac reverse remodeling and interconnecting mechanisms in type 4 cardiorenal syndrome

doi: 10.3389/fneph.2024.1455036

Figure Lengend Snippet: (A) displays the distribution of post-KT FGF23 levels based on the hypertension status. (B) shows that the patients with larger LA volumes had the worst NHYA class.

Article Snippet: FGF23 levels were quantified using the Human FGF23 monoclonal antibody and R&D Systems reagent (Minneapolis, MN, USA).

Techniques:

Journal: Frontiers in Nephrology

Article Title: Role of kidney transplantation in long-term cardiac reverse remodeling and interconnecting mechanisms in type 4 cardiorenal syndrome

doi: 10.3389/fneph.2024.1455036

Figure Lengend Snippet: Biochemical and echocardiographic characteristics grouped according the basal LVEF and after KT.

Article Snippet: FGF23 levels were quantified using the Human FGF23 monoclonal antibody and R&D Systems reagent (Minneapolis, MN, USA).

Techniques:

Journal: bioRxiv

Article Title: Transgenic augmentation of erythroferrone in mice ameliorates anemia in adenine-induced chronic kidney disease

doi: 10.1101/2024.12.06.627111

Figure Lengend Snippet: WT and TG mice from (n=6-7 mice/group) were analyzed. Measured parameters include ( A ) serum phosphate, ( B ) serum intact iFGF23, and qPCR analysis of kidney tissue for ( C-G ) Slc34a1 and Slc34a3 ( encoding sodium-dependent phosphate transporters 2A and 2C), Cyp27b1 and Cyp24a1 ( encoding the enzymes that respectively generate and break down the active form of vitamin D, 1,25-dihydroxyvitamin D3) and Kl (encoding Klotho, the renal coreceptor for iFGF23). Data are mean ± SEM, analyzed by unpaired- t -test with Welch’s correction (two-tailed). *P <.05; ns = non-significant.

Article Snippet: Intact bioactive FGF23 (iFGF23) levels were assessed by ELISA (60-6800, QuidelOrtho).

Techniques: Two Tailed Test